20th-century advances in drug therapy in oncology - Part I

Journal of Clinical Pharmacology

Volumn 40, Issue 9, 2000, Pages 1007-1024

  Dutcher, Janice P ^a   Novik, Yelena ^a   O'Boyle, Kevin ^a   Marcoullis, George ^a   Secco, Christiane ^a   Wiernik, Peter H ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTHRAQUINONE DERIVATIVE; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; BLEOMYCIN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; CYTIDINE DERIVATIVE; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IDARUBICIN; INTERFERON; IRINOTECAN; METHOTREXATE; MITOXANTRONE; PENTOSTATIN; PREDNISONE; RAZOXANE; SPARFOSIC ACID; TIOGUANINE; UNINDEXED DRUG; VALRUBICIN; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; BREAST CANCER; CANCER; CLINICAL PHARMACOLOGY; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RESEARCH; DRUG STRUCTURE; HISTORY OF MEDICINE; HODGKIN DISEASE; HUMAN; NONHODGKIN LYMPHOMA; NONHUMAN; REVIEW; TREATMENT OUTCOME;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; DNA; DRUG DELIVERY SYSTEMS; HISTORY, 20TH CENTURY; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; RNA;

EID: 0033667814     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700022009620     Document Type: Review

References (183)

1. Temporary remissions in acute leukemia in children produced by folic antagonist 4-amethopteroylgiutamic acid (Aminopterin)
2. Antifolates
3. Chemotherapy of neoplastic diseases
4. Methotrexate therapy in rheumatoid arthritis: 15 Years experience
5. Methotrexate for psoriasis
6. Cyclosporine vs methotrexate for graft-vs-host disease prevention in patients given marrow grafts for leukemia: Long-term follow-up of three controlled trials
7. The effect of methotrexate on intracellular folate pools in human MCF-7 breast cancer cells: Evidence for direct inhibition of purine synthesis
8. Effect of methotrexate on intracellular folate pools in purified myeloid precursor cells from normal human bone marrow
9. Relationship of reduced folate changes to inhibition of DNA synthesis induced by methotrexate in L1210 cells in vivo
10. Enhanced inhibition of thymidylate synthase methotrexate polyglutamates
11. Mechanism of thymidylate synthase inhibition by methotrexate in human neoplastic cell lines and normal human myeloid progenitor cells
12. Accumulation of DNA strand breaks and methotrexate cytotoxicity
13. Methotrexate-resistant Chinese hamster ovary cells have amplified a 135-kilobase pair region that includes the dihydrofolate reductase gene
14. Characterization of transport-mediated methotrexate resistance in human tumor cells with antibodies to the membrane carrier for methotrexate and tetrahydrofolate cofactors
15. The relative contribution of drug concentration and duration of exposure to mouse bone marrow toxicity during continuous methotrexate infusion
16. The effect of vincristine on methotrexate uptake and inhibition of DNA synthesis by human lymphoblastoid cells
17. Schedule-dependent synergism and antagonism between methotrexate and L-asparaginase
18. Moderate dose methotrexate, vincristine, asparaginase and dexamethasone for treatment of adult acute lymphocytic leukemia
19. Long-term follow-up of treatment and potential cure of adult acute lymphocytic leukemia with MOAD: A non-anthracycline containing regimen
20. A randomized comparison of high-dose infusion methotrexate versus standard dose weekly therapy in head and neck squamous cancer
21. Effectiveness of high-dose infusion of methotrexate followed by leucovorin in carcinomas of the head and neck
22. Ten-year results with CMF-based adjuvant chemotherapy in resectable breast cancer
23. Evolving concepts in the systemic adjuvant treatment of breast cancer
24. Cisplatin and 5-fluorouracil vs the same plus bleomycin and methotrexate in recurrent squamous cell carcinoma of the head and neck
25. Combination therapy with methotrexate and 5-fluorouracil: A prospective randomized clinical trial of order of administration
26. The reversal of methotrexate cytotoxicity to mouse bone marrow cells by leucovorin and nucleosides
27. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity
28. Pharmacokinetic monitoring of high-dose methotrexate
29. Phase II clinical trial with high-dose methotrexate therapy and citrovorum factor rescue
30. Effects of the large infrequent doses of amethopterin on acute leukemia in children
31. Methotrexate infusions and intensive supportive care in the management of children with acute lymphocytic leukemia: Follow-up report
32. Comparison of two schedules of intermediate dose methotrexate and cytarabine consolidation therapy for childhood B-precursor cell acute lymphoblastic leukemia
33. Methotrexate distribution in cerebrospinal fluid after intravenous, ventricular, and lumbar injections
34. Neurotoxicity and elevated cerebrospinal fluid methotrexate concentration in meningeal leukemia
35. Active transport of methotrexate from cerebrospinal fluid in humans
36. The intracerebral penetration of intraventricularly administered methotrexate: A quantitative autoradiographic study
37. Ten years' experience with methotrexate and folinic acid as primary therapy for gestational trophoblastic disease
38. Modified triple chemotherapy in the management of high-risk metastatic gestational trophoblastic tumors
39. Cytidine analogues
40. Arabinosyl cytosine: A useful agent in the treatment of acute leukemia in adults
41. Biochemical and cellular pharmacology of cytosine arabinoside
42. Membrane transport influences the rate of accumulation of cytosine arabinoside in human leukemia cells
43. A comparative trial of daunorubicin, cytosine arabinoside, and thioguanine and a combination of the three agents for the treatment of acute myelocytic leukemia
44. Cytosine arabinoside and daunorubicin therapy in acute nonlymphocytic leukemia
45. Intensive post-remission chemotherapy in adults with acute myeloid leukemia
46. 15-Year follow-up of adult patients with acute myeloid leukemia: A study BCRC 7802
47. Phase II study of mitoxantrone and 5-azacytidine for accelerated and blast crisis of chronic myelogenous leukemia: A study of the Eastern Cooperative Oncology Group
48. Continuous infusion of low dose 5-aza-2deoxycytidine in elderly patients with high risk myelodysplastic syndrome
49. Clinical evaluation of a new antimetabolite, 6-mercaptopurine, in the treatment of leukemia and allied diseases
50. Clinical pharmacology of oral thioguanine in acute myelogenous leukemia
51. Purine antimetabolites
52. Prolonged survival of human kidney homografts by immunosuppressive drug therapy
53. Cellular metabolism of nucleoside analogs in CLL: Implications for drug development
54. Fludarabine phosphate in the treatment of chronic lymphocytic leukemia: Biology, clinical impact and future directions
55. Fludarabine: A review of its pharmacological properties and therapeutic potential in malignancy
56. Fludarabine and epirubicin in the treatment of chronic lymphocytic leukemia: A German multicenter phase II study
57. Multicenter prospective randomized trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukemia. The French Cooperative Group on CLL
58. Results of fludarabine and prednisone therapy in 264 patients with lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment
59. The impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: An intergroup study (CALGB 9011)
60. Activity of fludarabine in previously treated non-Hodgkin's low grade lymphoma: Results of an Eastern Cooperative Oncology Group study
61. Pentostatin: Future directions
62. Deoxycoformycin in the treatment of leukemias and lymphomas
63. Pentostatin induces durable remissions in hairy cell leukemia
64. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: An intergroup study
65. Deoxycoformycin in the treatment of patients with hairy cell leukemia: Results of a Spanish collaborative study of 80 patients
66. Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine
67. Pentostatin in prolymphocytic leukemia: Phase II trial of the European Organization for Research and Treatment of Cancer leukemia study group
68. Pentostatin in T-cell malignancies: A phase II trial of the EORTC. Leukemia Cooperative Group
69. Pentostatin therapy of T-cell lymphomas with cutaneous manifestations
70. Pentostatin (2'-deoxycoformycin) in the treatment of cutaneous T-cell lymphoma
71. 2-Chlorodeoxyadenosine (2-CDA): A potent chemotherapeutic and immunosuppressive nucleoside
72. Antileukemic and immunosuppressive activity of 2-chloro-2'-deoxyadenosine
73. Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine
74. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications
75. Weekly intermittent 2-CDA is less toxic and equally efficacious when compared to continuous infusion in hairy cell leukaemia
76. Long-term outcome of hairy cell leukemia treated with 2-chlorodeoxyadenosine
77. Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia
78. Cladribine for untreated or early low-grade non-Hodgkin's lymphoma
79. 5-Fluoropyrimidines
80. Acute effect of 5-fluorouracil on cytoplasmic and nuclear dihydrofolate reductase messenger RNA metabolism
81. Utilization of 5-fluoro-2'-deoxyuridine triphosphate and 5-fluoro-2'-deoxycytidine triphosphate in DNA synthesis by DNA polymerases alpha and beta from calf thymus
82. Comparative DNA strand breakage induced by FUra and FdUrd in human ileocecal adenocarcinoma (HCT-8) cells: Relevance to cell growth inhibition
83. A clinical pharmacological evaluation of hepatic arterial infusion of 5-fluoro-2'-deoxyuridine and 5-fluorouracil
84. Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion
85. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program Study
86. Toxicities and complications of implanted pump hepatic arterial and intravenous floxuridine infusion
87. Biochemical modulation: Application of laboratory models to the clinic
88. Weekly irinotecan (CPT-11), leucovorin, and fluorouracil is superior to daily x 5 leucovorin/5FU in patients with previously untreated metastatic colorectal cancer
89. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus
90. Postoperative combined radiation and chemotherapy improves disease-free survival and overall survival in resected adenocarcinoma of the stomach and G.E. junction
91. Adjuvant therapy for adenocarcinoma of the rectum
92. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: Results from National Surgical Adjuvant Breast and Bowel Protocol C-03
93. Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portavein fluorouracil hepatic infusion: Preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02
94. When good enzymes go bad: Conversion of topoisomerase II to a cellular toxin by antineoplastic drugs
95. Strategies for prevention of anthracycline cardiotoxicity
96. Daunorubicin in the treatment of acute myelocytic leukemia
97. Traitment des leucemies aigues myeloblastiques
98. Daunorubicin in the therapy of acute granulocytic leukemia
99. A randomized trial of daunorubicin and a combination of prednisolone, vincristine, 6-mercaptopurine, and methotrexate in adult acute nonlymphocytic leukemia
100. Comparative study of cytosine arabinoside therapy alone and combined with thioguanine, mercaptopurine, or daunorubicin in acute myelocytic leukemia
101. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia
102. Etoposide in acute nonlymphocytic leukemia
103. Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia
104. A novel energy dependent mechanism reducing daunorubicin accumulation in acute myeloid leukemia
105. Significantly lower p-glycoprotein expression in acute promyelocytic leukemia than other types of acute myeloid leukemia: Immunological, molecular and functional studies
106. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: A CALGB study
107. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia
108. Cytarabine plus idarubicin or daunorubicin as induction therapy and consolidation therapy for previously untreated patients with acute myeloid leukemia
109. A phase III trial comparing idarubicin or daunorubicin in combination with cytarabine in acute myelogenous leukemia: A Southeastern Cancer Study Group experience
110. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells
111. Comparison of the intracellular pharmacokinetics of daunorubicin and idarubicin in patients with acute leukemia
112. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL)
113. A randomized study of mitoxantrone plus cytarabine versus daunomycin plus cytarabine in the treatment of previously untreated adult patients with acute nonlymphocytic leukemia
114. A randomized trial of high dose cyclophosphamide, vincristine, and prednisone plus or minus doxorubicin (CVP vs CAVP) with long-term follow-up in advanced non-Hodgkin's lymphoma
115. Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy
116. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: A dose-finding pilot study
117. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: A dose-finding pilot study
118. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: Results of a prospective randomized trial
119. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma
120. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma
121. Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma
122. CHOP vs. ProMACE-CytaBOM in the treatment of aggressive non-Hodgkin's lymphomas: Long-term results of a multicenter randomized trial
123. A randomised comparison of a third-generation regimen (PACEBOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin's lymphoma: A British National Lymphoma Investigation report
124. CHOP is the standard regimen in patients > 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: Results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group
125. A phase II trial of 200% ProMACE-CytaBOM in patients with previously untreated aggressive lymphomas: Analysis of response, toxicity, and dose intensity
126. Phase II trial of idarubicin in patients with advanced lymphoma
127. Phase III comparative trial using CHOP vs CIOP in the treatment of advanced intermediate-grade non-Hodgkin's lymphoma
128. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy
129. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma
130. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
131. Infusional cyclophosphamide, doxorubicin, and etoposide in relapsed and resistant non-Hodgkin's lymphoma: Evidence for a schedule-dependent effect favoring infusional administration of chemotherapy
132. Infusional cyclophosphamide, doxorubicin and etoposide in HIV-related non-Hodgkin's lymphoma: A follow-up report of a highly active regimen
133. Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease
134. Salvage chemotherapy in Hodgkin's disease irradiation failures: Superiority of doxorubicin-containing regimens over MOPP
135. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD
136. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alternation of MOPP with ABVD: A European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial
137. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgldn's disease: Ten-year results
138. Treatment of advanced Hodgkin's disease with chemotherapy-comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: A report from the National Cancer Institute of Canada Clinical Trials Group
139. MOPP/ABVD hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: The 8-year results of the intergroup trial
140. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: A preliminary report
141. Treatment of advanced untreated Hodgkin's disease with SCAB: An alternative to MOPP
142. Treatment of advanced-stage Hodgkin's disease: Alternating noncrossresistant MOPP/CABS is not superior to MOPP
143. Mitoxantrone, vinblastine, and lomustine (CCNU) (MVC): A highly active regimen for advanced and poor-prognosis Hodgkin's disease
144. Long-term results from MOPPEBVCAD chemotherapy with optional limited radiotherapy in advanced Hodgkin's disease
145. Sequential chemotherapy (etoposide, vinblastine, and doxorubicin) and subtotal lymph node radiation for patients with localized Hodgkin disease and unfavorable prognostic features
146. A longitudinal study of cardiac function in children with cancer over 40 months
147. Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study
148. Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: A reference
149. 5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study
150. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from national Surgical Adjuvant Breast and Bowel Project B-22
151. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: Findings from national Surgical Adjuvant Breast and Bowel Project B-25
152. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma
153. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer
154. Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: Feasibility and efficacy
155. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer
156. Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer
157. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer
158. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: A European Organization for Research and Treatent of Cancer randomized study with cross-over
159. Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group
160. Phase II trial of doxorubicin and paclitaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: An Eastern Cooperative Oncology Group study
161. Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients
162. Epirubicin: A review of its efficacy as adjuvant therapy and in the treatment of metastatic disease in breast cancer
163. Doubling of the epirubicin dosage within the 5-fluorouracil, epirubicin and cyclophosphamide regimen: A prospective, randomized, multicentric study on antitumor effect and quality of life in advanced breast cancer
164. A phase II trial of high dose epirubicin in patients with advanced breast carcinoma
165. Cardiotoxicity of epirubicin/paclitaxel-containing regimens: Role of cardiac risk factors
166. Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients
167. Phase II trial of N, N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine. HCL and doxorubicin chemotherapy in metastatic breast cancer: A National Cancer Institute of Canada clinical trials group study
168. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
169. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM90
170. Long term followup of treatment and potential cure of adult acute lymphocytic leukemia with MOAD: A non-anthracycline containing regimen
171. Chemotherapy versus chemoimmunotherapy for small-cell undifferentiated carcinoma of the lung
172. Adriamycin: A new effective agent in the therapy of disseminated sarcomas
173. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: A study of the European Organization for Research and Treatent of Cancer Soft Tissue and Bone Sarcoma Group
174. A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing's sarcoma and rhabdomyosarcoma
175. Eight-hour infusion versus bolus injection of doxorubicin in the EAP regimen in patients with advanced gastric cancer: A prospective randomised trial
176. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder
177. A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma
178. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma results of a randomized phase III clinical trial
179. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma: International pegylated liposomal doxorubicin study group
180. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma
181. Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin
182. Lattice intrahepatic doxorubicin with and without in-flow occlusion: A pharmacokinetic study of direct liver injection